U-H Mellqvist

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

Meletios Α. Dimopoulos, Antonio Palumbo, Michel Attal et al. · Leukemia · 2011 · 117 citations

Medicine, Pharmacology, Pharmacotherapy +14

NK cell‐mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites

Mats Brune, Markus Hansson, U-H Mellqvist et al. · European Journal Of Haematology · 1996 · 67 citations

Life Sciences, Hematology, Immunology +12

A Randomised Placebo Controlled Study With Melphalan/Prednisone Vs Melphalan/Prednisone/Thalidomide: Quality Of Life And Toxicity

Nina Gulbrandsen, Anders Waage, Peter Gimsing et al. · Lund University Publications (Lund University) · 2008 · 23 citations

Medicine, Pharmacology, Pharmacotherapy +10

Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial

Peter Gimsing, Øyvind Hjertner, Niels Abildgaard et al. · Bone Marrow Transplantation · 2015 · 22 citations · Full text

Medicine, Hematology, Oncology +16

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994–2009

Sara Rosengren, U-H Mellqvist, Hareth Nahi et al. · Bone Marrow Transplantation · 2016 · 20 citations · Full text

Medicine, Hematology, Surgery +17